Protagonist Therapeutics (NASDAQ:PTGX) Stock Price Up 4.6% Following Analyst Upgrade

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) was up 4.6% on Thursday after Citigroup raised their price target on the stock from $115.00 to $125.00. Citigroup currently has a buy rating on the stock. Protagonist Therapeutics traded as high as $101.43 and last traded at $101.5950. Approximately 187,169 shares changed hands during mid-day trading, a decline of 75% from the average daily volume of 754,789 shares. The stock had previously closed at $97.09.

Other equities analysts have also issued research reports about the stock. Barclays raised their price objective on shares of Protagonist Therapeutics from $113.00 to $119.00 and gave the company an “overweight” rating in a research report on Thursday. HC Wainwright increased their price target on shares of Protagonist Therapeutics from $80.00 to $117.00 and gave the stock a “buy” rating in a research note on Friday, January 30th. The Goldman Sachs Group raised their price target on shares of Protagonist Therapeutics from $65.00 to $95.00 and gave the company a “neutral” rating in a report on Tuesday, March 3rd. Johnson Rice reaffirmed a “buy” rating on shares of Protagonist Therapeutics in a research note on Wednesday. Finally, Truist Financial upped their price objective on shares of Protagonist Therapeutics from $88.00 to $110.00 and gave the stock a “buy” rating in a report on Monday, January 5th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $102.54.

Insider Buying and Selling at Protagonist Therapeutics

In related news, Director William D. Waddill sold 20,000 shares of the business’s stock in a transaction dated Friday, February 6th. The stock was sold at an average price of $83.68, for a total transaction of $1,673,600.00. Following the completion of the transaction, the director owned 7,825 shares of the company’s stock, valued at approximately $654,796. The trade was a 71.88% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Asif Ali sold 46,203 shares of the stock in a transaction that occurred on Tuesday, January 27th. The shares were sold at an average price of $83.13, for a total value of $3,840,855.39. Following the sale, the chief financial officer owned 60,320 shares of the company’s stock, valued at approximately $5,014,401.60. The trade was a 43.37% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 203,167 shares of company stock worth $16,889,199 in the last quarter. 4.90% of the stock is owned by corporate insiders.

Key Protagonist Therapeutics News

Here are the key news stories impacting Protagonist Therapeutics this week:

• Positive Sentiment: FDA approval of ICOTYDE triggers a $50 million milestone payment to Protagonist and makes the company eligible for 6–10% royalties plus up to $580 million in future milestones — a near-term cash boost and multi-year revenue upside. Access Newswire approval release
• Positive Sentiment: Wall Street commentary highlights that J&J’s FDA approval should create “significant value” for Protagonist by validating the IL‑23R oral-peptide approach and improving commercial prospects. MSN article
• Positive Sentiment: Citigroup raised its price target to $125 and maintained a Buy rating, signaling material upside (~22% from the cited reference price) and likely supporting investor demand. Benzinga note on Citi upgrade
• Positive Sentiment: Barclays increased its target to $119 and kept an Overweight rating, adding institutional endorsement of the approval’s commercial impact. Benzinga note on Barclays upgrade
• Neutral Sentiment: Industry coverage argues Protagonist’s first approval could pressure larger immunology incumbents — a thematic assessment that highlights competitive opportunity but does not change the company’s near-term revenue mechanics. BioSpace analysis
• Neutral Sentiment: Recent Seeking Alpha transcripts and slides from company/J&J commentary provide execution and commercialization details; useful for modeling royalty timing and market uptake but not immediate cash beyond the announced $50M. Seeking Alpha transcript slides
• Negative Sentiment: Protagonist’s recent quarterly results showed an EPS and revenue miss, large negative margins and no current product revenue — underscoring that most of the company’s value now rests on milestone/royalty receipts and future commercialization rather than recurring sales today. MarketBeat financial summary

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of PTGX. Farther Finance Advisors LLC grew its stake in shares of Protagonist Therapeutics by 110.6% in the fourth quarter. Farther Finance Advisors LLC now owns 297 shares of the company’s stock worth $26,000 after acquiring an additional 156 shares during the last quarter. Greenline Wealth Management LLC bought a new stake in Protagonist Therapeutics in the 4th quarter valued at $27,000. Salomon & Ludwin LLC bought a new stake in Protagonist Therapeutics in the 3rd quarter valued at $29,000. EverSource Wealth Advisors LLC grew its position in Protagonist Therapeutics by 138.9% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 540 shares of the company’s stock worth $36,000 after purchasing an additional 314 shares during the last quarter. Finally, Abich Financial Wealth Management LLC bought a new position in shares of Protagonist Therapeutics during the 3rd quarter worth about $62,000. 98.63% of the stock is currently owned by institutional investors and hedge funds.

Protagonist Therapeutics Trading Up 4.4%

The firm’s fifty day moving average price is $86.37 and its 200-day moving average price is $80.45. The company has a market cap of $6.46 billion, a P/E ratio of -49.57 and a beta of 2.23.

Protagonist Therapeutics (NASDAQ:PTGX) last released its earnings results on Wednesday, February 25th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.53) by ($0.16). Protagonist Therapeutics had a negative net margin of 282.83% and a negative return on equity of 19.89%. The company had revenue of $7.44 million during the quarter, compared to the consensus estimate of $14.92 million. As a group, research analysts forecast that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current fiscal year.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.